Datapoint: Lilly Pulls Olumiant in Lupus

Eli Lilly and Incyte on Jan. 28 said they have ended Olumiant’s Phase 3 trial for lupus, citing mixed results. The companies also gave an update on the JAK inhibitor’s status in atopic dermatitis, warning that the agency may issue a Complete Response Letter. For the treatment of rheumatoid arthritis, Olumiant currently holds covered or better status for 67% of all insured lives under the pharmacy benefit. About 11% of all covered lives have preferred access to Olumiant, with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 1/31/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today